bullish

ASRT: Looking Ahead to 2023

358 Views04 Feb 2023 04:27
In 2023, while Cambia revenue goes away it should be offset by growth from Indocin, Otrexup, and newly acquired Sympazan. ASRT's stock remains cheap compared to peers
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
chart-bar
x